The success of Sildenafil initially fueled a period of growth for pharma, but recent shifts present a complicated picture for investors. Lower-cost alternatives are eating into earnings, and continued litigation add further risk to the situation. While some companies could still see gains from adjacent services, the broader trajectory suggests a me